Cagle P., Allen T.C. et al. (eds.) Precision Molecular Pathology of Lung Cancer

2nd edition. — Springer, 2018. — 289 p. — (Molecular Pathology Library).This new edition provides the latest information and insights into the molecular basis for lung cancer. Since the publication of the previous edition of this volume, dramatic changes have occurred with the classification of lung cancer, biomarker testing, and molecular therapy. The book covers these changes, providing updates and new insights on the background of lung cancer, testing methods, and the molecular pathology of specific cell types, including adenocarcinoma, squamous cell carcinoma, small cell carcinoma, and precursor and preinvasive lesions.Authored by experts in the field, Precision Molecular Pathology of Lung Cancer, Second Edition remains one of the few books that comprehensively covers the new molecular pathology of lung cancer and is a valuable resource for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, and thoracic radiologists.Background
Precision Medicine in Lung Cancer
Lung Cancer Epidemiology and Demographics
Genetic Susceptibility to Lung Cancer
Lung Cancer Stem Cells
The 2015 World Health Organisation Classification of Lung Cancer
Testing Methods
The Molecular Pathology of Lung Cancer: Pre-analytic Considerations
Mutation Testing of Lung Cancer Biomarkers (Excluding IHC and NGS)
Translocation Testing of Lung Cancer Biomarkers
Immunohistochemistry of Lung Cancer Biomarkers
Next-Generation and Third-Generation Sequencing of Lung Cancer Biomarkers
Molecular Pathology of Specific Cell Types
Mutations as Predictive Biomarkers for Adenocarcinoma
Translocations as Predictive Biomarkers in Lung Cancer
Predictive Biomarkers for Squamous Cell Carcinoma
Molecular Pathology of Small Cell Carcinoma
Molecular Pathology of Uncommon Carcinomas
Biology of Lung Cancer Metastases
Precursor and Preinvasive Lesions
General and Emerging Fields in Molecular Pathology of Lung Cancer
Prognostic Biomarkers in Lung Cancer
Targeted Therapies for Lung Cancer
Immunotherapy and Lung Cancer: Programmed Death 1 and Its Ligand as a Target for Therapy
Liquid Biopsies